# DESCRIPTION

## FIELD OF THE INVENTION

- introduce invention field

## BACKGROUND OF THE INVENTION

- introduce integrin activation
- describe VLA-4 conformational regulation
- discuss cAMP/PKG and cGMP/PKG signaling pathways
- highlight nitric oxide signaling in hematopoietic progenitor and stem cell mobilization

## SUMMARY OF THE INVENTION

- introduce nitric oxide/cGMP signaling pathway
- describe VLA-4 affinity down-modulation
- outline method of treating VLA-4-related cell adhesion disorders
- list nitric oxide donors
- list nitric oxide-independent activators of soluble guanylyl cyclase
- list cell permeable analogs of cGMP
- describe co-administration of active ingredients
- outline method of treating cancer
- outline method of treating atherosclerosis and myocardial ischemia
- outline method of treating tumor metastasis
- outline method of preventing metastasis
- describe diagnostic method
- describe screening method

## DETAILED DESCRIPTION OF THE INVENTION

- define singular and plural forms
- introduce antibody terminology
- describe antibody structure and function
- motivate use of functional equivalents
- describe production of functional equivalents
- introduce hybrid antibodies
- describe preparation of polyclonal antibodies
- describe preparation of monoclonal antibodies
- motivate use of chimeric and humanized antibodies
- describe production of chimeric and humanized antibodies
- cite standard techniques for molecular biology
- define fluorophores and their properties
- describe detection methods for biological samples
- define stem cells and their types
- describe morphology determination of cell samples
- outline high-throughput format for imaging and detection
- describe use of transmission electron microscopy
- cite applicable methods and materials for high-throughput imaging
- describe high-throughput assay systems
- outline use of multiple labels in multiplex amplification reactions
- describe adaptability to high-throughput screening
- cite conventional biology methods and software
- describe computer software products for computational biology
- outline use of computer program products and software
- describe methods for providing information over networks
- describe distributed processing architecture
- outline data storage and access methods
- explain web-based service implementation
- define term "compound"
- describe measurement of protein or gene expression
- outline immunoassay, activity assay, and binding assay methods
- describe detection of antibodies reactive to cGMP and/or VLA-4
- outline ELISA and Western blot methods
- define term "patient" or "subject"
- describe VLA-4-related cell adhesion disorders
- outline nitric oxide/cGMP signaling pathway modulators
- describe nitric oxide donors
- describe nitric oxide-independent activators of soluble guanylyl cyclase and cell permeable analogs of cGMP
- define biological sample
- define body fluid
- define effective
- define treatment
- define co-administration
- describe methods of treatment
- describe pharmaceutical compositions
- list additional VLA-4 antagonists
- describe pharmaceutical composition formulation
- describe administration routes
- describe subject or patient
- describe administration of effective amount

### EXAMPLES

- summarize nitric oxide/cGMP signaling pathway effects
- motivate integrin de-activation mechanism
- describe nitric oxide donor effects on VLA-4 ligand binding
- introduce small molecule probes for nitric oxide/cGMP pathway
- describe nitric oxide/cGMP signaling pathway in leukocytes
- introduce Example 1: effects of nitric oxide/cGMP signaling in leukocytes
- describe materials and methods for Example 1
- introduce Example 2: experiments with U937 cells and nitric oxide donor
- describe nitric oxide donor-induced rapid decrease in VLA-4 specific ligand binding
- introduce Example 3: materials and methods
- describe experimental design for detecting VLA-4 conformational changes
- summarize significance of nitric oxide donor effects on VLA-4 ligand binding
- present experimental results
- describe LDV-FITC probe binding and dissociation
- analyze kinetic data
- discuss activator of soluble guanylyl cyclase
- describe dissociation rate analysis
- discuss effect of nitric oxide-independent activator
- analyze dissociation rate constants
- describe materials and methods
- present example 4
- describe real-time aggregation experiments
- discuss effect of cell permeable analog of cGMP
- describe effect of NO/cGMP signaling pathway activation
- discuss VLA-4-VCAM-1 dependent cell adhesion
- analyze cell aggregation data
- conclude on NO/cGMP signaling pathway

### Discussion of Experimental Results

- motivate integrin deactivation
- discuss NO-dependent VLA-4 deactivation
- discuss hematopoietic stem cell mobilization

### Conclusions

- summarize findings on nitric oxide/cGMP signaling pathway

## Methods

### Materials

- list materials

### Cell Lines and Transfectant Construct

- describe cell lines and transfectant construct

### Kinetic Analysis of Binding and Dissociation of VLA-4 Specific Ligand

- describe kinetic analysis of binding and dissociation

### Cell Adhesion Assay

- describe cell adhesion assay

### Statistical Analysis

- describe statistical analysis

## Abbreviations

- list abbreviations

